RXRX Recursion Pharmaceuticals Inc
Price (delayed)
$6.62
Market cap
$1.86B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.64
Enterprise value
$1.47B
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients
Highlights
Recursion Pharmaceuticals's gross profit has soared by 73% from the previous quarter
The gross margin has surged by 60% since the previous quarter
The debt has surged by 76% since the previous quarter and by 70% year-on-year
Recursion Pharmaceuticals's net income has decreased by 44% YoY and by 6% from the previous quarter
Key stats
What are the main financial stats of RXRX
Market
Valuations
Earnings
Shares outstanding
281.11M
Market cap
$1.86B
Enterprise value
$1.47B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.69
Price to sales (P/S)
32.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.71
Revenue
$49.64M
EBIT
-$380.29M
EBITDA
-$339.17M
Free cash flow
-$342.16M
Per share
Balance sheet
Liquidity
EPS
-$1.64
Free cash flow per share
-$1.41
Book value per share
$2.46
Revenue per share
$0.2
TBVPS
$2.83
Total assets
$775.86M
Total liabilities
$191.41M
Debt
$89.88M
Equity
$584.45M
Working capital
$436.29M
Debt to equity
0.15
Current ratio
6.07
Quick ratio
5.56
Net debt/EBITDA
1.14
Margins
Efficiency
Dividend
EBITDA margin
-683.3%
Gross margin
17.1%
Net margin
-755.4%
Operating margin
-796.5%
Return on assets
-57.3%
Return on equity
-79.5%
Return on invested capital
-254.5%
Return on capital employed
-55.1%
Return on sales
-766.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RXRX stock price
How has the Recursion Pharmaceuticals stock price performed over time
Intraday
0.76%
1 week
8.17%
1 month
-1.78%
1 year
-22.75%
YTD
-32.86%
QTD
-11.73%
Financial performance
How have Recursion Pharmaceuticals's revenue and profit performed over time
Revenue
$49.64M
Gross profit
$8.51M
Operating income
-$395.36M
Net income
-$374.93M
Gross margin
17.1%
Net margin
-755.4%
Recursion Pharmaceuticals's gross profit has soared by 73% from the previous quarter
The gross margin has surged by 60% since the previous quarter
The net margin has declined by 45% year-on-year
The operating margin has contracted by 45% YoY but it has grown by 2.2% from the previous quarter
Growth
What is Recursion Pharmaceuticals's growth rate over time
Valuation
What is Recursion Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.69
P/S
32.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.71
The company's EPS fell by 20% YoY
RXRX's equity is up by 46% since the previous quarter and by 25% year-on-year
RXRX's price to book (P/B) is 38% lower than its last 4 quarters average of 4.3
RXRX's price to sales (P/S) is 24% lower than its last 4 quarters average of 42.0
RXRX's revenue is up by 7% since the previous quarter
Efficiency
How efficient is Recursion Pharmaceuticals business performance
The company's return on sales fell by 47% YoY
Recursion Pharmaceuticals's return on assets has decreased by 44% YoY
Recursion Pharmaceuticals's return on equity has decreased by 35% YoY
RXRX's ROIC is up by 15% QoQ but it is down by 4.1% YoY
Dividends
What is RXRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RXRX.
Financial health
How did Recursion Pharmaceuticals financials performed over time
The company's current ratio has surged by 61% YoY and by 31% QoQ
The quick ratio has surged by 54% year-on-year and by 36% since the previous quarter
The debt is 85% smaller than the equity
The debt has surged by 76% since the previous quarter and by 70% year-on-year
RXRX's equity is up by 46% since the previous quarter and by 25% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.